Trials / Completed
CompletedNCT01658202
Nicotine Patch Bioequivalence Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the relative bioavailability of nicotine following single application of a new transdermal formulation to that of a reference formulation. 4 single 24hour applications separated by 48hour intervals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | V0116 transdermal patch (Test treatment ) | |
| DRUG | Nicotine transdermal patch (Reference Treatment ) |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2012-08-06
- Last updated
- 2012-12-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01658202. Inclusion in this directory is not an endorsement.